<DOC>
	<DOC>NCT01733004</DOC>
	<brief_summary>This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.</brief_summary>
	<brief_title>A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>Advanced malignant solid tumors for which no curative therapy exists that has recurred or pgrogressed following standard therapy Eighteen years of age or above Able to understand and sign an informed consent (or have a legal representative who is able to do so) Measurable disease according to RECIST v1.1 ECOG Performance Score of 0 or 1 Adequate bone marrow, hepatic, renal and cardiac function Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM141 Active infection or fever &gt; 38.5Â°C during screening visits or on the first scheduled day of dosing Symptomatic CNS disease Received other recent antitumor therapy Pregnant or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Hepatocellular Carcinoma</keyword>
	<keyword>Oncology</keyword>
	<keyword>Phase I</keyword>
	<keyword>ErbB3</keyword>
	<keyword>IGF-1R</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Abraxane</keyword>
</DOC>